TaiMed Biologics Inc (4147):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:TaiMed Biologics Inc (4147) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8106
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
TaiMed Biologics Inc (TMB) is a biotechnology company that provides novel medicines for the prevention and treatment of viral infectious diseases. The company provides pipeline products such as TMB-355, TMB-607 and TMB-571, among others. It offers TMB-355 which is a proprietary humanized anti-CD4 monoclonal antibody, developed for the treatment of HIV, and others. TMB provides TMB-607 which is a novel HIV-1 protease inhibitor that is developed using a nanotechnology formulation for subcutaneous and intramuscular injections. The company offers TMB-571 which is a small molecule inhibitor against wild-type neuraminidases. It operates in Taiwan and the US. TMB is headquartered in Taipei, Taiwan.

TaiMed Biologics Inc (4147) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TaiMed Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Theratechnologies Enters into Co-Marketing Agreement with TaiMed Biologics 10
Licensing Agreements 11
TaiMed Biologics Enters into Licensing Agreement with ADARC 11
TaiMed Biologics Enters into Licensing Agreement with Rockefeller University 12
Equity Offering 13
TaiMed Biologics Plans to Raise USD0.2 Million in Private Placement of Shares 13
TaiMed Biologics Raises USD104.8 Million in Public Offering of Shares 14
Asset Transactions 15
Theratechnologies Acquires Commercial Rights to Ibalizumab from TaiMed Biologics 15
TaiMed Biologics Inc – Key Competitors 16
TaiMed Biologics Inc – Key Employees 17
TaiMed Biologics Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TaiMed Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TaiMed Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Theratechnologies Enters into Co-Marketing Agreement with TaiMed Biologics 10
TaiMed Biologics Enters into Licensing Agreement with ADARC 11
TaiMed Biologics Enters into Licensing Agreement with Rockefeller University 12
TaiMed Biologics Plans to Raise USD0.2 Million in Private Placement of Shares 13
TaiMed Biologics Raises USD104.8 Million in Public Offering of Shares 14
Theratechnologies Acquires Commercial Rights to Ibalizumab from TaiMed Biologics 15
TaiMed Biologics Inc, Key Competitors 16
TaiMed Biologics Inc, Key Employees 17
TaiMed Biologics Inc, Subsidiaries 18

List of Figures
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[TaiMed Biologics Inc (4147):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Abbott Laboratories (ABT)-製薬・医療分野:企業M&A・提携分析
    Summary Abbott Laboratories (Abbott) is a healthcare company, which discovers, develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company’s products comprise specialized medicines; me …
  • BOOM Logistics Ltd (BOL):企業の財務・戦略的SWOT分析
    BOOM Logistics Ltd (BOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ACell Inc:企業の製品パイプライン分析
    Summary ACell Inc (ACell) is a medical device company that offers products for wounds and various surgical procedures. The company develops and manufactures products to facilitate the body’s ability to repair and remodel tissue. Its products portfolio includes burn matrix products, multilayer wound …
  • Brokk AB:企業の戦略的SWOT分析
    Brokk AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Tuesday Morning Corporation (TUES):企業の財務・戦略的SWOT分析
    Tuesday Morning Corporation (TUES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Albemarle Corporation:企業の戦略・SWOT・財務情報
    Albemarle Corporation - Strategy, SWOT and Corporate Finance Report Summary Albemarle Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • MAN Energy Solutions SE:企業の戦略的SWOT分析
    MAN Energy Solutions SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Laboratoires Thea SA:企業の戦略的SWOT分析
    Laboratoires Thea SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Merck & Co Inc (MRK)-製薬・医療分野:企業M&A・提携分析
    Summary Merck & Co Inc (Merck) focuses on the discovery, development, manufacture and commercialization of prescription pharmaceuticals, biologic therapies, vaccines and animal healthcare products. It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respirato …
  • Kia Motors Corporation:企業の戦略・SWOT・財務分析
    Kia Motors Corporation - Strategy, SWOT and Corporate Finance Report Summary Kia Motors Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • JA Solar Holdings Co Ltd (JASO):企業の財務・戦略的SWOT分析
    JA Solar Holdings Co Ltd (JASO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Kowa Co Ltd (7807):企業の財務・戦略的SWOT分析
    Kowa Co Ltd (7807) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Keysight Technologies Inc:戦略・SWOT・企業財務分析
    Keysight Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary Keysight Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Chr. Hansen Holding AS (CHR):企業の財務・戦略的SWOT分析
    Chr. Hansen Holding AS (CHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Benefitfocus Inc (BNFT):企業の財務・戦略的SWOT分析
    Summary Benefitfocus Inc (Benefitfocus) is a technology service provider that offers cloud- based software solutions. The company provides cloud-based benefits management platform for shopping, enrolling, managing and exchanging benefit information for employers, insurance carriers, brokers, and con …
  • Carmat SAS (ALCAR)-医療機器分野:企業M&A・提携分析
    Summary Carmat SAS (Carmat) is a medical equipment company that offers artificial organs. The company offers development of innovative artificial organs, artificial heart and other vital organs. Its artificial heart products consists of an implantable heart, and components which help connect to an e …
  • IXICO Plc (IXI)-製薬・医療分野:企業M&A・提携分析
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints. The company provides clinical trial services for assessing the safety and efficacy of drugs. Its product portfolio includes web-based platform to transf …
  • Multan Electric Power Company:企業の戦略的SWOT分析
    Multan Electric Power Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Enel Americas SA:企業の戦略・SWOT・財務情報
    Enel Americas SA - Strategy, SWOT and Corporate Finance Report Summary Enel Americas SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Orlen Upstream Sp zoo:石油・ガス:M&Aディール及び事業提携情報
    Summary Orlen Upstream Sp zoo (Orlen Upstream), a subsidiary of Polski Koncern Naftowy Orlen SA is an oil and gas company that offers petroleum products and natural gas. The company provides products such as motor fuel, diesel, LPG, marine fuel, aviation fuel, greases, kerosene, brake fluids, techni …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆